Two common and potentially deadly heart diseases can be caused by mutations in the same gene. Surprisingly, though, these two ...

Feline Hypertrophic Cardiomyopathy (HCM) is the most common heart disease in cats, affecting felines of all breeds and ...

Affecting 1 in 500 people, hypertrophic cardiomyopathy is a condition in which the walls of the left ventricle, the heart's main pumping chamber, become abnormally thick. "HCM is one of the primary ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

Edgewise Therapeutics shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top ...

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

The American College of Cardiology honored cardiologist and researcher Jeffrey Towbin, MD, with the ACC Lifetime Achievement ...

KUTV — Feline Hypertrophic Cardiomyopathy (HCM) is the most common heart disease in cats, affecting felines of all breeds and ages. This condition causes the walls of the heart’s left ...